|January 23, 2014|
|09:25 EDT||SNTI, SNTI, SRNE, SRNE, SPEX, SPEX, CDXC, CDXC, CBMX, CBMX, SSET, SSET, OPK, OPK, CGIX, CGIX||RedChip Companies to hold a virtual conference|
RedChip Emerging Growth Showcase is being held on January 22-23 with webcasted presentations to begin on January 23 at 9:30 am. Webcast Link
News For OPK;CGIX;SNTI;SRNE;SPEX;CDXC;CBMX;SSET From The Last 14 Days
|August 3, 2015|
|06:13 EDT||SRNE||Sorrento Therapeutics in-licenses four late-stage clinical biobetter antibodies|
Sorrento Therapeutics announced that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. Under the terms of the agreement, Sorrento will develop and market these 4 monoclonal antibodies for the North American, European and Japanese market. Each of the mAbs has completed a Phase III study; two are currently in registration for marketing approval in China, while the other two are under data analyses for subsequent NDA submission in China. One of the biobetter mAbs is based on a Top 10-selling oncology drug and the other a Top 5-selling antibody to treat auto-immune diseases. Together these 4 mAbs target an established market with combined annual global sales in 2014 in excess of $13B. Based on a study by GBI Research the global biosimilar market could reach an estimated $55B by 2020.
|July 29, 2015|
|07:59 EDT||SRNE||Sorrento Therapeutics price target raised to $26 from $17 at Brean Capital|
Brean Capital raised its price target on Sorrento Therapeutics (SRNE) to $26 from $17 as they believe the successful Nantkwest (NK) IPO has validated the company and its strategy. The firm noted Sorrento is an equal partner in the ownership of Nantkwest and thus feels it deserves a similar valuation, which is not priced in. Brean Capital reiterated its Buy rating on Sorrento shares.
|July 28, 2015|
|13:43 EDT||OPK||OPKO Health announces FDA acceptance of NDA for Rayaldee |
OPKO Health announced that the U.S. FDA has accepted for review OPKO’s New Drug Application for calcifediol modified-release capsules, proposed trade name, Rayaldee. In the NDA, OPKO seeks approval of Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. OPKO expects written notification of NDA acceptance along with the Prescription Drug User Fee Act date in the FDA’s 74-Day letter, which the company expects to receive by mid-August 2015. The NDA is supported by data from three randomized, double-blind, placebo-controlled studies and one open-label extension study conducted in the targeted patient population at a total of 105 U.S. sites. These studies met all primary efficacy and safety endpoints, as previously announced.
|July 27, 2015|
|17:10 EDT||SPEX||Mitchell Kopin reports 4.99% passive stake in Spherix |
|July 24, 2015|
|08:02 EDT||CGIX||Cancer Genetics suspends active on 'at-the-market' equity |
Cancer Genetics announced that it has suspended activity on the sale of shares through an "at-the-market" offering.
|08:02 EDT||CGIX||Cancer Genetics suspends at-the-market equity offering|
|July 23, 2015|
|10:05 EDT||SRNE||High option volume stocks|
Subscribe for More Information
|07:31 EDT||CGIX, CBMX||RedChip to hold a virtual conference|
2015 Global Online CEO Conference is being held on July 22-23 with webcasted presentations to begin on July 23 at 9:30 am. Webcast Link
|July 22, 2015|
|07:20 EDT||CGIX, CBMX||RedChip to hold a virtual conference|
Subscribe for More Information